Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 1789 • 2013 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, The 12 Individual Biomarkers That Comprise The Multiple Biomarker Disease Activity Score Relate Differentially To Clinical Response and Radiographic Progression: Results From a Randomized Trial
Karen Hambardzumyan¹, Saedis Saevarsdottir², Rebecca Bolce³, Kristina Forslind⁴, Sofia Ernestam⁵, Ingemar F. Petersson⁶, Pierre Geborek⁷, David Chernoff³, Douglas J. Haney³, Eric H. Sasso³ and Ronald F van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, ⁶Lund University, Lund, Sweden, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁸ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: In early rheumatoid arthritis (eRA), clinical and radiographic predictors would be very useful for optimizing available therapies. Individual biomarkers and their combinations, such as…
Abstract Number: 710 • 2013 ACR/ARHP Annual Meeting
Interleukin-6 Driven STAT3 Phosphorylation In Circulating Lymphocytes Is Specific For CD4⁺ T Cells In Early Rheumatoid Arthritis
Amy E. Anderson¹, Christine Routledge¹, Philip Mawson², John D. Isaacs³ and Arthur G. Pratt³, ¹Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Musculoskeletal Directorate, The Freeman Hospital, Newcastle upon Tyne, United Kingdom, ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease, caused by a breakdown in self tolerance. Robust biomarkers are needed which, as well having…
Abstract Number: 1771 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany
Malte Wolff¹, Zheng-Yi Zhou², James Signorovitch², James W. Shaw³ and Arijit Ganguli³, ¹AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ²Analysis Group, Inc., Boston, MA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: The 2012 German rheumatoid arthritis (RA) treatment guidelines recommend sequential use of disease-modifying antirheumatic drugs (DMARDs) in a treat-to-target (T2T) framework. Biologics are recommended…
Abstract Number: 502 • 2013 ACR/ARHP Annual Meeting
Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort
Cécile Gaujoux-Viala¹, Laure Gossec², Maxime Dougados³, Francis Guillemin⁴ and Bruno Fautrel⁵, ¹EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Rheumatology, Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ³Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability [1]. The concept of favorable outcome…
Abstract Number: 2689 • 2013 ACR/ARHP Annual Meeting
Assessing Maintenance Of Remission After Withdrawal Of Etanercept Plus Methotrexate, Methotrexate Alone, Or Placebo In Early Rheumatoid Arthritis Patients Who Achieved Remission With Etanercept and Methotrexate: The Prize Study
Paul Emery¹, Wolfgang Spieler², Maria Stopinska-Polaszewska³, Nikolay I Korshunov⁴, Jack Bukowski⁵, Ronald Pedersen⁶, Theresa Williams⁷, Stefanie Gaylord⁷ and Bonnie Vlahos⁷, ¹Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, ²Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ³Family Physicians Specialists Clinic, Torun, Poland, ⁴State Budgetary Healthcare Institution of Yaroslavl Region, Yaroslavl, Russia, ⁵Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Department of Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: In the PRIZE study patients (pts) with early (mean 6 mos. since symptom onset) moderate-severe rheumatoid arthritis (RA), who achieved remission after open-label treatment…
Abstract Number: 1772 • 2013 ACR/ARHP Annual Meeting
Better Cost-Effectiveness and Worker Productivity In Triple DMARD Therapy Versus Methotrexate Monotherapy In Early Rheumatoid Arthritis; Cost-Utility Analysis Of The Treach Trial
P.H.P. de Jong¹, A.E.a.M. Weel², J.J. Luime³, P.J. Barendregt², A.H. Gerards⁴, P.A. van der Lubbe⁴, M.H. de Jager⁵, P.B. de Sonnaville⁶, D. van Zeben⁷, B.A. Grillet⁸ and J.M.W. Hazes³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁶Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁷Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁸Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: In the treatment in the Rotterdam Early Arthritis Cohort (tREACH) trial we showed that treatment goals were attained faster and maintained with less treatment…
Abstract Number: 480 • 2013 ACR/ARHP Annual Meeting
Levels Of Circulating Mirnas Before and After 12 Months Therapy With Dmards In Patients With Early Rheumatoid Arthritis
Mária Filková¹, Borbala Aradi², Ladislav Senolt³, Klara Prajzlerova⁴, Serena Vettori², Herman F. Mann⁵, Jiri Vencovsky⁴, K. Pavelka⁶, Beat A. Michel⁷, Renate E Gay², Steffen Gay² and Astrid Jüngel², ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Institute of Rheumatology, Department of Clinical and Experimental Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁶Department of Clinical and Experimental Rheumatology, Charles University, Prague, Czech Republic, ⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: The altered expression of cellular miRNAs in the immune and resident cells involved in the pathogenesis of rheumatoid arthritis (RA) has been shown to…
Abstract Number: 2646 • 2013 ACR/ARHP Annual Meeting
Cost-Effectiveness Analysis Of Triple Therapy Versus Etanercept Plus Methotrexate In Early Aggressive Rheumatoid Arthritis: Analysis Based On The TEAR Trial
Hawre Jalal¹, Jeffrey R. Curtis², Stacey Cofield³, Larry W. Moreland⁴, James R. O'Dell⁵ and Kaleb Michaud⁶, ¹Health Polisy and Management, University of Minnesota, Minneapolis, MN, ²Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The long-term cost-effectiveness of triple therapy (methotrexate [MTX], sulfasalazine [SSZ], hydroxychloroquine [HCQ]) disease modifying anti-rheumatic drugs (DMARDs) compared to a combination of MTX and…
Abstract Number: 1693 • 2013 ACR/ARHP Annual Meeting
Initial Triple DMARD Therapy Is More Efficient Than Methotrexate Monotherapy In Recent Onset Rheumatoid Arthritis; 1-Year Data Of a Randomized Clinical Trial (tREACH)
P.H.P. de Jong¹, J.M.W. Hazes², K.H. Han³, A.M. Huisman⁴, D. van Zeben⁵, P.A. van der Lubbe⁶, A.H. Gerards⁶, B. van Schaeybroeck⁷, P.B. de Sonnaville⁸, M.V. Krugten⁹, J.J. Luime² and A.E.A.M. Weel³, ¹Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁵Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁶Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁷Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, Netherlands
Background/Purpose: Recommended treatment for DMARD naïve patients is methotrexate (MTX) with or without glucocorticoids (GCs). Triple DMARD therapy however is not recommended, because well proven…
Abstract Number: 449 • 2013 ACR/ARHP Annual Meeting
Work Instability In Early Rheumatoid Arthritis With Elevated Risk Of Employment Loss: Effects Of Adalimumab/Methotrexate Combination Therapy Versus Methotrexate In a Randomized Clinical Trial
Arthur Kavanaugh¹, Josef S. Smolen², Arijit Ganguli³, Hartmut Kupper³, Mary Cifaldi³, Naijun Chen³ and Dennis Revicki⁴, ¹University of California, San Diego, La Jolla, CA, ²Medical University of Vienna, Vienna, Austria, ³AbbVie Inc., North Chicago, IL, ⁴United BioSource, Bethesda, MD
Background/Purpose: Intensive treatment of early rheumatoid arthritis (RA) has been shown to reduce functional disability over time and to positively impact employment outcomes. Adalimumab (ADA)…
Abstract Number: 2359 • 2013 ACR/ARHP Annual Meeting
Impact Of Etanercept-Methotrexate Treatment Withdrawal On Patient-Reported Outcomes In Patients With Early Rheumatoid Arthritis (PRIZE Trial)
Piotr Wiland¹, B Combe², Oliver FitzGerald³, Hasan Tahir⁴, Stefanie Gaylord⁵, Theresa Williams⁵, Ronald Pedersen⁶, Jack Bukowski⁷, Bonnie Vlahos⁵ and Sameer Kotak⁸, ¹Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ²Hôpital Lapeyronie, Montpellier, France, ³Department of Rheumatology, St.Vincent's University Hospital, Dublin, Ireland, ⁴Barts Health NHS Trust, London, United Kingdom, ⁵Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁶Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁸Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Active rheumatoid arthritis (RA) is commonly associated with impairment of physical function and health-related quality of life (QoL), as well as work disability. The…
Abstract Number: 1358 • 2013 ACR/ARHP Annual Meeting
No Differences In Patient-Reported Outcomes By Methotrexate Dose Among Early Rheumatoid Arthritis Patients Treated Concomitantly With Adalimumab: Results From The Concerto Trial
Roy Fleischmann¹, Alan Kivitz², Ronald F van Vollenhoven³, James W. Shaw⁴, Stefan Florentinus⁵, Piyalal M. Karunaratne⁴, Hartmut Kupper⁶, Maxime Dougados⁷ and Gerd Burmester⁸, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²Altoona Center for Clinical Research, Duncansville, PA, ³ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie, Rungis, France, ⁶AbbVie Deutschland GmBH & Co. KG, Ludwigshafen, Germany, ⁷Hopital Cochin, René Descartes University, Paris, France, ⁸Department of Rheumatology & Clinical Immunology, Charité-Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany
Background/Purpose: Methotrexate (MTX) in combination with the tumor necrosis factor inhibitor adalimumab (ADA) is an effective therapy for treating rheumatoid arthritis (RA), but the minimum…
Abstract Number: 426 • 2013 ACR/ARHP Annual Meeting
Characteristics of Protocol-Specified Responders/Non-Responders Treated With Etanercept Plus Methotrexate in Period 1 of the Prize Study
Paul Emery¹, Annette Szumski², Jack Bukowski³, Eustratios Bananis² and Lisa Marshall⁴, ¹Institute Rheumatic and Musculoskeletal Medicine University of Leeds, Leeds, United Kingdom, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc., Collegeville, PA
Background/Purpose: Although frequently effective, treatment with synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) does not adequately control disease activity in all patients. Prompt identification of…
Abstract Number: 2294 • 2013 ACR/ARHP Annual Meeting
The Role Of Patient Global Disease Activity Score In The Definition Of American College Of Rheumatology/European League Against Rheumatism Remission In Very Early Rheumatoid Arthritis From The Norwegian Very Early Arthritis Clinic
Maria Dahl Mjaavatten¹, Anne Julsrud Haugen², Halvor Nygaard³, Olav Bjørneboe⁴, Patrik Stolt⁵, Cathrine Thunem⁶ and Tore Kristian Kvien^1,7, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Østfold Hospital Trust, Fredrikstad, Norway, ³Dept. of Rheumatology, Revmatismesykehuset Lillehammer, Lillehammer, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Sandvika, Norway, ⁵Dept. of Rheumatology, Innlandet Hospital Trust, Brumunddal, Norway, ⁶Dept. of Rheumatology, Betanien Hospital, Skien, Norway, ⁷Faculty of Medicine, University of Oslo, Oslo, Norway
Background/Purpose: In the ACR/EULAR criteria remission can be defined in two ways, either by fulfilment of 4 Boolean criteria or by a Simplified Disease Activity…
Abstract Number: 1361 • 2013 ACR/ARHP Annual Meeting
Stringent Therapies Improve Clinical, Radiographic and Magnetic Resonance Imaging Outcome In Early-Stage Rheumatoid Arthritis Patients From Japanese Population: Longitudinal Study From Nagasaki Early Arthritis Cohort
Mami Tamai^1,2, Yoshikazu Nakashima³, Junko Kita⁴, Ayuko Takatani⁴, Ayako Nishino³, Takahisa Suzuki³, Yoshiro Horai³, Akitomo Okada⁵, Shin-ya Kawashiri^3,6, Naoki Iwamoto³, Kunihiro Ichinose³, Kazuhiko Arima⁶, Hideki Nakamura³, Tomoki Origuchi⁷, Masataka Uetani⁸, Katsumi Eguchi⁹ and Atsushi Kawakami³, ¹Center for Health & Community Medicine, Nagasaki University, Nagasaki, Japan, ²Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁴Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁵Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, ⁶Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁷Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁹Sasebo City General Hospital, Sasebo, Nagasaki, Japan
Background/Purpose: Prognosis of the patients with rheumatoid arthritis (RA) nowadays is supposed to become better by treat-to-target (T2T) strategy. Osteitis determined by magnetic resonance imaging…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].